ArticleBMC gastroenterology2025
Prognostic importance of CD47 expression on survival of colorectal cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CD47-mediated efferocytosis in diseases: A comprehensive review.Molecular biology reports · 2026Review
- Research advances on CD47 in digestive system cancers: from molecular mechanisms to clinical translation.Molecular medicine (Cambridge, Mass.) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe exact value of cluster of differentiation 47 (CD47), known as the "don't eat me" signal, in colorectal cancer (CRC) has not been clearly revealed. Thus, we investigated the impact of its expression on the overall survival (OS) of CRC patients who underwent colectomy.
methodsNinety-eight CRC patients were included. The patient population was grouped into two categories based on the median value of CD47 expression examined with immunohistochemistry: negative (< median) and positive (≥ median). The estimation of OS was executed with the Kaplan-Meier method, and the difference in prognostic groups was tested with the log-rank test. The association of CD47 with OS was examined with univariate and multivariate Cox regression models.
resultsCD47 expression was recorded in 56.1% of CRC patients. Among the clinicopathological variables, the only significant difference between the prognostic groups was the presence of lymph node involvement (p = 0.005). The OS of patients with CD47 expression was lower than those with no CD47 expression (39.3 months vs. not reached, p = 0.001, respectively). Additionally, in metastatic CRC patients treated with biologic agents, patients with CD47 expression had numerically inferior OS times than those without CD47 expression (37 months vs. 58.5 months, p = 0.05, respectively). Our multivariate analysis showed that CD47 was an independent prognostic factor associated with OS in this cohort (HR: 2.142, p = 0.006).
conclusionOur study suggests that CD47 may serve as a potential prognostic marker and a promising therapeutic target for anti-CD47-based treatments in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.